Renal Cell Carcinoma News and Research

Latest Renal Cell Carcinoma News and Research

Clinical data for cabozantinib to be presented at ASCO annual meeting

Clinical data for cabozantinib to be presented at ASCO annual meeting

2 Apr 2012
Papillary renal cell carcinoma patients face low tumour re-occurrence and cancer-related death rates

Papillary renal cell carcinoma patients face low tumour re-occurrence and cancer-related death rates

29 Mar 2012
Penn oncologist to discuss role of autophagy in fighting cancer at AAAS annual meeting

Penn oncologist to discuss role of autophagy in fighting cancer at AAAS annual meeting

19 Feb 2012
Exelixis reports preliminary data from cabozantinib phase 1b trial on RCC

Exelixis reports preliminary data from cabozantinib phase 1b trial on RCC

3 Feb 2012
Circadian's VGX-100 human antibody improves corneal graft survival

Circadian's VGX-100 human antibody improves corneal graft survival

30 Jan 2012
Inlyta receives FDA approval for treatment of advanced kidney cancer

Inlyta receives FDA approval for treatment of advanced kidney cancer

30 Jan 2012
Elevated blood lead levels put smokers at higher risk for renal cell carcinoma

Elevated blood lead levels put smokers at higher risk for renal cell carcinoma

24 Jan 2012
Pfizer, SFJ to conduct axitinib Phase 3 trial in renal cell carcinoma

Pfizer, SFJ to conduct axitinib Phase 3 trial in renal cell carcinoma

9 Jan 2012
Circadian initiates VGX-100 Phase 1 trial in advanced solid tumours

Circadian initiates VGX-100 Phase 1 trial in advanced solid tumours

9 Jan 2012
Astellas, AVEO announce results of tivozanib and sorafenib comparison trial on RCC

Astellas, AVEO announce results of tivozanib and sorafenib comparison trial on RCC

3 Jan 2012
Van Andel studies distinguish cancer subtypes and provide promising new drug targets

Van Andel studies distinguish cancer subtypes and provide promising new drug targets

30 Dec 2011
AVEO initiates enrollment in tivozanib and mFOLFOX6 Phase 2 combination trial for CRC

AVEO initiates enrollment in tivozanib and mFOLFOX6 Phase 2 combination trial for CRC

22 Dec 2011
Updated data from Novartis Afinitor plus everolimus Phase III study on advanced breast cancer

Updated data from Novartis Afinitor plus everolimus Phase III study on advanced breast cancer

8 Dec 2011
Novartis to showcase 160 presentations on breast cancer, hematological disease drugs at SABCS and ASH

Novartis to showcase 160 presentations on breast cancer, hematological disease drugs at SABCS and ASH

3 Dec 2011
AVEO, Boehringer Ingelheim enter development and manufacturing agreement for ficlatuzumab

AVEO, Boehringer Ingelheim enter development and manufacturing agreement for ficlatuzumab

2 Dec 2011
Conference highlights advances in evidence-based integrative therapies for cancer

Conference highlights advances in evidence-based integrative therapies for cancer

11 Nov 2011
AVEO third quarter net loss increases to $23.8 million

AVEO third quarter net loss increases to $23.8 million

2 Nov 2011
Vegenics receives IND approval from FDA for VGX-100 Phase I study in late stage cancers

Vegenics receives IND approval from FDA for VGX-100 Phase I study in late stage cancers

31 Oct 2011
ONR's FARSIGHT can help doctors identify and classify cancer-related cells

ONR's FARSIGHT can help doctors identify and classify cancer-related cells

7 Oct 2011
Circadian subsidiary submits IND application to FDA to initiate VGX-100 study against cancer

Circadian subsidiary submits IND application to FDA to initiate VGX-100 study against cancer

1 Oct 2011

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback